scholarly journals 312. Unplanned Readmission after Hospitalization with Staphylococcus aureus Bacteremia in Children: a Multistate Population Based Study

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S152-S153
Author(s):  
Kengo Inagaki ◽  
Md Abu Yusuf Ansari ◽  
Charlotte V Hobbs
Keyword(s):  
Staphylococcus Aureus ◽  
Hematologic Malignancy ◽  
Adult Population ◽  
Multivariable Analysis ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Interquartile Range ◽  
Unplanned Readmission ◽  
Catheter Related Infection ◽  
Staphylococcus Aureus Bacteremia

Abstract Background Staphylococcus aureus bacteremia is associated with substantial mortality and morbidity. Readmission is becoming increasingly recognized as an important quality measure and can inform optimal patient care. We previously reported readmission analyses in the setting of S. aureus bacteremia in the adult population. However, readmission has not been characterized in children. Methods We performed a population-based longitudinal observational study using the State Inpatient Database from New York, Florida, and Washington states, 2009–2015. Children aged 18 years or younger hospitalized with S. aureus bacteremia were included. The outcome of unplanned readmission within 30 days and 90 days of discharge was assessed by developing Cox proportional hazards regression models. Results Of 1240 children that were included in the analysis, 18% (223 children) had unplanned readmission within 30 days after discharge, and 28.3% were readmitted within 90 days. On multivariable analysis, children with underlying conditions of hematologic malignancy (hazard ratio, HR: 1.67, 95% confidence interval, CI: 1.09–2.56) and catheter related infection (HR: 1.79, 95%CI: 1.31–2.45) had higher hazards of readmission, whereas coexisting skin and soft tissue infection (HR: 0.42, 95%CI: 0.24–0.71) was associated with a lower rate of readmission (Table, Figure). In addition to these, solid tumor malignancy and longer length of stay during the original hospitalization were associated with higher hazards of 90-day readmission. The median cost of the original hospitalization for S. aureus bacteremia was $29914 (interquartile range, IQR: $13276-$71284), and that of 30-day readmission was $10956 (interquartile range, IQR: $5765-$24753). Table Figure Conclusion Unplanned readmission is common and costly among children who survived S. aureus bacteremia, occurring in 18% and 28.3% within 30 and 90 days after discharge, respectively. Those with malignancies and catheter related infection had higher hazards of unplanned readmission. Further research is needed to identify optimal interventions to reduce readmission rates associate with S. aureus bacteremia in children. Disclosures All Authors: No reported disclosures

scholarly journals Association of glaucoma with 10-year mortality in a population-based longitudinal study in urban Southern China: the Liwan Eye Study

BMJ Open ◽  
2021 ◽  
Vol 11 (10) ◽  
pp. e040795
Author(s):  
Langhua Wang ◽  
Zhuoting Zhu ◽  
Wenyong Huang ◽  
Jane Scheetz ◽  
Mingguang He
Keyword(s):  
Southern China ◽  
Open Angle Glaucoma ◽  
Adult Population ◽  
Multivariable Analysis ◽  
Significant Risk ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Angle Closure ◽  
Secondary Outcome ◽  
Rank Test

ObjectivesTo investigate the association between glaucoma and 10-year mortality rate in an adult population in China.DesignPopulation-based cohort study.SettingThe Liwan Eye Study, China.Participants1405 baseline participants aged 50 years and older were invited to attend a 10-year follow-up examination.Primary and secondary outcome measuresThe International Society of Geographic and Epidemiologic Ophthalmology criteria was used to define glaucoma. Detailed information of mortality was confirmed using the Chinese Centre for Disease Control and Prevention. Presenting visual impairment (PVI) was defined as a presenting visual acuity of less than 20/40 in the better-seeing eye. The 10-year mortality rates were compared using the log-rank test. Cox proportional hazards regression models were used to investigate the association between glaucoma and mortality.ResultsA total of 1372 (97.7%) participants with available gonioscopic data were included in the analysis. Of these, 136 (9.9%), 33 (2.4%) and 21 (1.5%) participants had primary angle closure (PAC) suspect (PACS), PAC and PAC glaucoma (PACG), and 29 (2.1%) had primary open angle glaucoma (POAG). After 10 years, 306 (22.3%) participants were deceased. The 10-year mortality was significantly associated with PACG (HR, 2.15, 95% CI 1.14 to 4.04, p=0.018) but not associated with PAC (HR, 1.27, 95% CI 0.67 to 2.39, p=0.463), PACS (HR, 1.32, 95% CI 0.95 to 1.83, p=0.099) and POAG (HR, 0.74, 95% CI 0.36 to 1.49, p=0.395) when age and gender were adjusted for. This association was no longer statistically significant (HR, 1.60, 95% CI 0.70 to 3.61, p=0.263) when covariables, such as income, education, body mass index, PVI, history of diabetes and hypertension, were adjusted for. Larger vertical cup-to-disc ratio (VCDR >0.30) was only a significant risk factor in multivariable analysis (HR, 1.60, 95% CI 1.11 to 2.33, p=0.011).ConclusionsPACG was significantly associated with higher long-term mortality, but this association was likely to be confounded by other systemic risk factors. VCDR >0.3 was the only independent predictor, implying that it may be a marker of ageing and frailty.

scholarly journals 2625. Incidence of Bronchiolitis Requiring Hospitalization in the First 2 years of Life Among Healthy Term Infants with Different Races/Ethnicities: A Population-based Longitudinal Study

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S914-S915
Author(s):  
Kengo Inagaki ◽  
Chad Blackshear ◽  
Charlotte V Hobbs
Keyword(s):  
New York ◽  
Socioeconomic Status ◽  
Proportional Hazards ◽  
New York State ◽  
Multivariable Analysis ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Indigenous Populations ◽  
Term Infants ◽  
Race Ethnicity

Abstract Background Race/ethnicity is currently not considered a risk factor for bronchiolitis, except for indigenous populations in western countries. We sought to determine the incidence of hospitalization with bronchiolitis among different races/ethnicities, because such information can lead to more tailored preventive care. Methods We performed a population-based longitudinal observational study using the State Inpatient Database from New York state. Infants born between 2009 and 2013 at term without comorbidities were followed for the first 2 years of life, up to 2015. We calculated incidence among different race/ethnicity groups, and evaluated risks by developing Cox proportional hazards regression models. Results Of 877,465 healthy term infants, 10 356 infants were hospitalized with bronchiolitis. Overall, incidence was 11.8 per 1,000 births. Substantial difference in infants born in different seasons was observed (Figure 1). The incidence in non-Hispanic white, non-Hispanic black, Hispanic, and Asian infants was 8.6, 15.4, 19.1, and 6.5 per 1,000 births, respectively (table). On multivariable analysis adjusting for socioeconomic status, the risks remained substantially high among non-Hispanic black (hazard ratio [HR] 1.42, 95% confidence interval [CI]: 1.34–1.51) and Hispanic infants (HR 1.77, 95% CI: 1.67–1.87), particularly beyond 2–3 months of age, whereas Asian race was protective (HR 0.62, 95% CI: 0.56–0.69) (Figure 2, 3). Conclusion The risks of bronchiolitis hospitalization in the first 2 years of life was substantially higher among infants with non-Asian minority infants, particularly beyond 2–3 months of age. Further research efforts to identify effective public health interventions in each race/ethnic groups with varied socioeconomic status, such as improvement in access to care and anticipatory guidance, is warranted to overcome health disparity. Disclosures All authors: No reported disclosures.

scholarly journals Influence of Acetylsalicylic Acid Use on Risk and Outcome of Community-Acquired Staphylococcus aureus Bacteremia: A Population-Based Study

2019 ◽  
Vol 6 (9) ◽  
Author(s):  
Jesper Smit ◽  
Michael Dalager-Pedersen ◽  
Kasper Adelborg ◽  
Achim J Kaasch ◽  
Reimar W Thomsen ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Acetylsalicylic Acid ◽  
Population Based ◽  
Socioeconomic Indicators ◽  
Medical Databases ◽  
Staphylococcus Aureus Bacteremia ◽  
Increased Risk ◽  
First Time ◽  
Population Controls

Abstract Objective To investigate the influence of acetylsalicylic acid (ASA) use on risk and outcome of community-acquired Staphylococcus aureus bacteremia (CA-SAB). Method We used population-based medical databases to identify all patients diagnosed in northern Denmark with first-time CA-SAB and matched population controls from 2000–2011. Categories for ASA users included current users (new or long-term users), former users, and nonusers. The analyses were adjusted for comorbidities, comedication use, and socioeconomic indicators. Results We identified 2638 patients with first-time CA-SAB and 26 379 matched population controls. Compared with nonusers, the adjusted odds ratio (aOR) for CA-SAB was 1.00 (95% confidence interval [CI], 0.88–1.13) for current users, 1.00 (95% CI, 0.86–1.16) for former users, 2.04 (95% CI, 1.42–2.94) for new users, and 0.95 (95% CI, 0.84–1.09) for long-term users. Thirty-day cumulative mortality was 28.0% among current users compared with 21.6% among nonusers, yielding an adjusted hazard rate ratio (aHRR) of 1.02 (95% CI, 0.84–1.25). Compared with nonusers, the aHRR was 1.10 (95% CI, 0.87–1.40) for former users, 0.60 (95% CI, 0.29–1.21) for new users, and 1.06 (95% CI, 0.87–1.31) for long-term users. We observed no difference in the risk or outcome of CA-SAB with increasing ASA dose or by presence of diseases commonly treated with ASA. Conclusions Use of ASA did not seem to influence the risk or outcome of CA-SAB. The apparent increased risk among new users may relate to residual confounding from the circumstances underlying ASA treatment initiation. Our finding of no association remained robust with increasing ASA dose and across multiple patient subsets.

scholarly journals 1067. Comparative Effectiveness of Nafcillin or Oxacillin, Cefazolin, and Piperacillin/Tazobactam in Methicillin-Sensitive Staphylococcus aureus Bacteremia

2018 ◽  
Vol 5 (suppl_1) ◽  
pp. S319-S319
Author(s):  
Maya Beganovic ◽  
Jaclyn Cusumano ◽  
Vrishali Lopes ◽  
Kerry LaPlante ◽  
Aisling Caffrey
Keyword(s):  
Staphylococcus Aureus ◽  
Nearest Neighbor ◽  
Proportional Hazards ◽  
Final Analysis ◽  
Cox Proportional Hazards ◽  
Inpatient Mortality ◽  
Staphylococcus Aureus Bacteremia ◽  
Hazard Ratios ◽  
Ocean Spray ◽  
Research Grant

Abstract Background β-Lactam antibiotics are recommended as first line for treatment of methicillin-sensitive Staphylococcus aureus (MSSA) bacteremia. The objective of this study was to compare effectiveness among β-lactam therapies in MSSA bacteremia patients that were exclusively treated with one antibiotic. Methods This was a retrospective cohort study of patients hospitalized at Veterans Affairs (VA) medical centers with MSSA bacteremia from January 1, 2002 to October 1, 2015. Patients were included if they were treated exclusively with nafcillin, oxacillin, cefazolin, or piperacillin/tazobactam (i.e., monotherapy with no changes in therapy). The primary outcome was 30-day mortality, and secondary outcomes were time to discharge, inpatient mortality, 30-day readmission, and 30-day S. aureus reinfection. Hazard ratios (HRs) and 95% confidence intervals (CI) were calculated using unadjusted, quintile adjusted, and propensity-score (PS) matched (nearest neighbor, 0.05 caliper) Cox proportional hazards regression. Results A total of 326 patients were included in the final analysis. When comparing nafcillin (n = 75)/oxacillin (n = 30) with cefazolin (n = 108), 30-day mortality was similar between groups (PS matched n = 40, HR 4.0, 95% CI 0.45–35.79), as were rates of the other outcomes assessed. When combining nafcillin/oxacillin with cefazolin, and comparing to piperacillin/tazobactam (n = 113), 30-day mortality was significantly lower in the nafcillin/oxacillin/cefazolin group (PS matched n = 66, HR 0.29, 95% CI 0.09–0.87). Inpatient mortality and 30-day mortality were significantly lower with nafcillin/oxacillin/cefazolin in PS-adjusted analyses (HR 0.29, 95% CI 0.11–0.73 and HR 0.23, 95% CI 0.10–0.50, respectively). Conclusion In hospitalized patients with MSSA bacteremia, no difference in mortality was observed between nafcillin/oxacillin and cefazolin in patients that were exclusively treated with these monotherapies. However, higher mortality was observed with piperacillin/tazobactam as compared with nafcillin/oxacillin/cefazolin, suggesting that it may not be as effective as other monotherapies for MSSA bacteremia. Disclosures K. LaPlante, Merck: Grant Investigator, Research grant. Pfizer Pharmaceuticals: Grant Investigator, Research grant. Allergan: Scientific Advisor, Honorarium. Ocean Spray Cranberries, Inc.: Grant Investigator and Scientific Advisor, Honorarium and Research grant. Achaogen, Inc.: Scientific Advisor, Honorarium. Zavante Therapeutics, Inc.: Scientific Advisor, Honorarium. A. Caffrey, Merck: Grant Investigator, Research grant. The Medicine’s Company: Grant Investigator, Research grant. Pfizer: Grant Investigator, Research grant.

scholarly journals Causes of Death after a Hospitalization with AKI

2017 ◽  
Vol 29 (3) ◽  
pp. 1001-1010 ◽  
Author(s):  
Samuel A. Silver ◽  
Ziv Harel ◽  
Eric McArthur ◽  
Danielle M. Nash ◽  
Rey Acedillo ◽  
...  
Keyword(s):  
General Population ◽  
Causes Of Death ◽  
Proportional Hazards ◽  
Adult Population ◽  
Gynecologic Cancer ◽  
Cardiovascular Death ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Administrative Databases ◽  
Standardized Mortality Ratios

Mortality after AKI is high, but the causes of death are not well described. To better understand causes of death in patients after a hospitalization with AKI and to determine patient and hospital factors associated with mortality, we conducted a population-based study of residents in Ontario, Canada, who survived a hospitalization with AKI from 2003 to 2013. Using linked administrative databases, we categorized cause of death in the year after hospital discharge as cardiovascular, cancer, infection-related, or other. We calculated standardized mortality ratios to compare the causes of death in survivors of AKI with those in the general adult population and used Cox proportional hazards modeling to estimate determinants of death. Of the 156,690 patients included, 43,422 (28%) died in the subsequent year. The most common causes of death were cardiovascular disease (28%) and cancer (28%), with respective standardized mortality ratios nearly six-fold (5.81; 95% confidence interval [95% CI], 5.70 to 5.92) and eight-fold (7.87; 95% CI, 7.72 to 8.02) higher than those in the general population. The highest standardized mortality ratios were for bladder cancer (18.24; 95% CI, 17.10 to 19.41), gynecologic cancer (16.83; 95% CI, 15.63 to 18.07), and leukemia (14.99; 95% CI, 14.16 to 15.85). Along with older age and nursing home residence, cancer and chemotherapy strongly associated with 1-year mortality. In conclusion, cancer-related death was as common as cardiovascular death in these patients; moreover, cancer-related deaths occurred at substantially higher rates than in the general population. Strategies are needed to care for and counsel patients with cancer who experience AKI.

scholarly journals Staphylococcus aureus bacteremia and cardiac implantable electronic devices in a county hospital setting: a population-based retrospective cohort study

2021 ◽  
Vol 126 (1) ◽  
Author(s):  
Sara Pichtchoulin ◽  
Ingrid Selmeryd ◽  
Elisabeth Freyhult ◽  
Pär Hedberg ◽  
Jonas Selmeryd
Keyword(s):  
Staphylococcus Aureus ◽  
Electronic Device ◽  
Hospital Setting ◽  
Population Based ◽  
County Hospital ◽  
Individual Risk ◽  
Hospital Death ◽  
Device Removal ◽  
Staphylococcus Aureus Bacteremia ◽  
Cardiac Implantable Electronic Devices

Background: Due to a high incidence of cardiac implantable electronic device-associated infective endocarditis (CIED-IE) in cases of Staphylococcus aureus bacteremia (SAB) and high mortality with conservative management, guidelines advocate device removal in all subjects with SAB. We aimed to investigate the clinical course of SAB in patients with a CIED (SAB+CIED) in a Swedish county hospital setting and relate it to guideline recommendations. Methods: All CIED carriers with SAB, excluding clinical pocket infections, in the County of Västmanland during 2010–2017 were reviewed retrospectively. Results: There were 61 cases of SAB+CIED during the study period, and CIED-IE was diagnosed in 13/61 (21%) cases. In-hospital death occurred in 19/61 (31%) cases, 34/61 (56%) cases were discharged with CIED device retained, and 8/61 (13%) cases were discharged after device removal. Subjects dying during hospitalization were elderly and diseased. No events was seen if the CIED was removed. Among four discharged cases with conservatively managed CIED-IE one relapse occured. Among 30 cases discharged with retained CIED and no evidence of IE, 22/30 (73%) cases had an uneventful follow-up, whereas adverse events secondary to overlooked CIED-IE were likely in 1/30 (3%) cases and could not be definitely excluded in additionally 4/30 (13%) cases. Conclusions: During the study period, management became more active and prognosis improved. The heterogeneity within the population of SAB+CIED suggests that a management strategy based on an individual risk/benefit analysis could be an alternative to mandatory device removal.

scholarly journals Impact of Age, Comorbidity, and Polypharmacy on Treatment and Survival for Aggressive Non-Hodgkin Lymphoma

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 26-27
Author(s):  
Laura Tapley ◽  
Pamela Skrabek ◽  
Pascal Lambert ◽  
Jenniebie Bravo ◽  
Kathleen Decker ◽  
...  
Keyword(s):  
Board Of Directors ◽  
Proportional Hazards ◽  
Hematologic Malignancy ◽  
Age Groups ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Advisory Committees ◽  
Substantial Impact ◽  
Curative Therapy ◽  
The Impact

Introduction: Non-Hodgkin's lymphoma (NHL) is the most prevalent hematologic malignancy, with most people diagnosed aged over 65 years (Alexander et. al. Int.J.Cancer 2007). Older populations have more comorbid health conditions, frailty, polypharmacy, and health resource use (Ogle et. al. Cancer 2000). The complex interplay of these factors may influence the prescription of curative therapy and prognosis. In trials evaluating NHL therapies, elderly patients are underrepresented, particularly those with frailty or comorbidity, resulting in knowledge gaps. We report a retrospective, population-based cohort study of aggressive NHL patients and examine the impact of age and its interaction with comorbidity and polypharmacy on treatment patterns and survival. Methods: Using the Manitoba Cancer Registry we identified patients aged over 18 years with NHL diagnosed from 2004-2015. We limited the cohort to aggressive NHL types using morphology codes. Data on demographics, stage, NHL type, comorbidities, polypharmacy, and chemotherapy were obtained from population-based provincial databases. Comorbidity was measured using Johns Hopkins ACG System software, which factored in all measured hospital-based and outpatient medical services utilized and collapsed them into one of six Resource Utilization Band (RUB) categories, from no use to very high user. Overall survival (OS) was calculated using Kaplan-Meier curves. Cox proportional hazards regression models were constructed to determine the interaction of age with a variety of factors. Multi-variable logistic regression was also used to examine the receipt of chemotherapy and the interaction with age. Results: In our cohort of 1,073 patients with aggressive NHL, 704 were treated with systemic chemotherapy. Treatment rates decreased with increasing age and medication count, while stage and comorbidity had little impact (Table 1). Median OS decreased with age among treated patients and was very short without chemotherapy (Table 1). Multivariate analyses found that individuals with increasing age, stage III, unknown stage, histology other than DLBCL, and higher medication counts were less likely to receive chemotherapy. For the receipt of chemotherapy, no age interactions were found. In addition, in patients who received chemotherapy, increased age and stage were associated with poorer survival, while more recent year of diagnosis improved survival. No age interactions with a substantial impact on survival were found. Conclusions: OS in aggressive NHL diminishes with increasing age, but is longer in those receiving chemotherapy across all age groups. Comorbidity and medication count influenced the receipt of chemotherapy and OS. Higher medication count was only independently associated with less likelihood of receiving chemotherapy, while comorbidity was not independent of other factors for either receipt of chemotherapy or OS. Disclosures Dawe: AstraZeneca Canada: Research Funding; AstraZeneca Canada: Membership on an entity's Board of Directors or advisory committees; Boehringer-Ingelheim: Honoraria; Merck Canada: Membership on an entity's Board of Directors or advisory committees.

scholarly journals Treatment-Free Survival in Patients With Differentiated Thyroid Cancer

2018 ◽  
Vol 103 (7) ◽  
pp. 2720-2727 ◽  
Author(s):  
Mousumi Banerjee ◽  
David Reyes-Gastelum ◽  
Megan R Haymart
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Radioactive Iodine ◽  
Survival Rates ◽  
Multivariable Analysis ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Primary Concern ◽  
Free Survival ◽  
Prognostic Groups

Abstract Objective Cancer recurrence is a primary concern for patients with differentiated thyroid cancer; however, population-level data on recurrent or persistent disease do not currently exist. The objective of this study was to determine treated recurrent or persistent thyroid cancer by using a population-based registry, identify correlates of poor treatment-free survival, and define prognostic groups for treatment-free survival. Methods In this population-based study, we evaluated treatment-free survival in 9273 patients from the Surveillance, Epidemiology, and End Results Program–Medicare with a diagnosis of differentiated thyroid cancer between 1998 and 2012. Treated recurrence was defined by treatment of recurrent or persistent differentiated thyroid cancer with surgery, radioactive iodine, or radiation therapy at ≥1 year after diagnosis. Multivariable analysis was performed with Cox proportional hazards regression, survival trees, and random survival forests. Results In this cohort the median patient age at time of diagnosis was 69 years, and 75% of the patients were female. Using survival tree analyses, we identified five distinct prognostic groups (P < 0.001), with a prediction accuracy of 88.7%. The 5-year treatment-free survival rates of these prognostic groups were 96%, 91%, 85%, 72%, and 52%, respectively, and the 10-year treatment-free survival rates were 94%, 87%, 80%, 64%, and 39%. Based on survival forest analysis, the most important factors for predicting treatment-free survival were stage, tumor size, and receipt of radioactive iodine. Conclusion In this population-based cohort, five prognostic groups for treatment-free survival were identified. Understanding treatment-free survival has implications for the care and long-term surveillance of patients with differentiated thyroid cancer.

scholarly journals Epidemiology and survival outcome of adult kidney, bladder, and prostate rhabdomyosarcoma: A SEER database analysis

Rare Tumors ◽  
2020 ◽  
Vol 12 ◽  
pp. 203636132097740
Author(s):  
Sagar R Patel ◽  
Caitlin P Hensel ◽  
Jiaxian He ◽  
Nicolas E Alcalá ◽  
James T Kearns ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Survival Data ◽  
Adult Population ◽  
Multivariable Analysis ◽  
Population Based ◽  
Soft Tissue Tumors ◽  
Seer Database ◽  
Adult Kidney ◽  
Population Demographic

Rhabdomyosarcoma (RMS) is rare in adulthood, accounting for 2%–5% of adult soft tissue tumors, and less than 20% occur in genitourinary organs. Given its rarity, survival data on adult kidney, bladder, and prostate RMSs is limited. In this population-based analysis, we performed an analysis of all adult RMS cases reported in Surveillance, Epidemiology, and End Results (SEER) database to understand prognostic factors among kidney, bladder, and prostate RMS. A query of the SEER database was performed from 1973 to 2016 for patients >18 of age with RMS. The final cohort consisted of 14 kidney, 35 bladder, and 21 prostate RMS cases in the adult population. Demographic, treatment, and survival data were obtained. Analysis was performed using Fisher’s exact test, survival analysis, and model. The median (range) age of diagnosis for adult bladder RMS was 65 years old (19–84) compared to 52.5 (28–68) and 42 (19–87) for kidney and prostate ( p = 0.007). About 78.6% of patients underwent surgical intervention. Five-year overall survival (OS) for adult kidney, bladder, and prostate RMS are 17.1% (2.9–41.6%), 22.2% (9.4–38.4%), and 33.0 (12.8–55.0%), respectively. OS was not statistically associated with primary site ( p = 0.209). On multivariable analysis, compared to adult bladder RMS, kidney RMS had a higher incidence of mortality (HR: 2.16, 95% CI 1.03–4.53, p = 0.041). Incidence of mortality from prostate RMS was not significantly different from bladder RMS (HR: 0.70, 95% CI 0.30–1.65, p = 0.411). Extent of disease (HR: 5.17, 95% CI 2.09–12.79, p < 0.001) and older age (HR 1.03, 95% CI 1.01–1.04, p = 0.002) were adverse prognostic factors for OS. Overall survival at 5 years for adult kidney, bladder, and prostate RMS is poor. Localized disease and younger age are prognostic factors for improved outcomes in adult RMS. Hence, early diagnosis and intervention appear paramount to improved survival for this rare malignancy in adulthood.

scholarly journals Unplanned Readmission within 28 Days of Hospital Discharge in a Longitudinal Population-Based Cohort of Older Australian Women

2020 ◽  
Vol 17 (9) ◽  
pp. 3136
Author(s):  
Dinberu S. Shebeshi ◽  
Xenia Dolja-Gore ◽  
Julie Byles
Keyword(s):  
Proportional Hazards ◽  
Hospital Admissions ◽  
Proportional Hazards Model ◽  
Population Based ◽  
Cox Proportional Hazards ◽  
Cox Proportional Hazards Model ◽  
Index Admission ◽  
Unplanned Readmission ◽  
Hazards Model ◽  
English Speaking

This study aimed to estimate the incidence of 28-day unplanned readmission among older women, and associated factors. Data were used from the 1921–1926 birth cohort of the Australian Longitudinal Study on Women’s Health. Linkage of self-reported survey data with the Admitted Patient Data Collection allowed the identification of hospital admissions for each woman and the corresponding baseline characteristics. The Cox proportional-hazards model was used to identify factors associated with time to unplanned readmission, using SAS software V 9.4. (SAS Institute, Cary, NC, USA). Of 2056 women with index unplanned admission, 363 (17.5%) were readmitted within 28 days of discharge, and of these 229 (11.14%) had unplanned readmission. Among women with unplanned readmission, 24% were for the same condition as for the index hospitalisation. Cardiovascular diseases were the main diagnoses for the index admission and readmission. Unplanned readmission risk was higher if not partnered (hazard ratio (HR) = 1.43, 95% confidence interval (CI): 1.05–1.95), of non-English speaking background (HR = 1.62%, 95% CI: 1.07–2.47), more than three days length of stay on index admission (HR = 1.41%, 95% CI: 1.04–1.90) and one or two of the assessed chronic diseases (HR = 1.68, 95% CI: 1.19–2.36). At least one in ten women had unplanned readmission at some time between ages 75–95 years. Women who are not partnered, not of English-speaking background, with longer hospital stay and those with multi-morbidity, may need further efforts during their stay and on discharge to mitigate unplanned readmission.

Sign in / Sign up

Export Citation Format

Share Document